Cargando…

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malani, D, Murumägi, A, Yadav, B, Kontro, M, Eldfors, S, Kumar, A, Karjalainen, R, Majumder, M M, Ojamies, P, Pemovska, T, Wennerberg, K, Heckman, C, Porkka, K, Wolf, M, Aittokallio, T, Kallioniemi, O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420795/ https://www.ncbi.nlm.nih.gov/pubmed/27833094 http://dx.doi.org/10.1038/leu.2016.314

Ejemplares similares

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
por: Pugliese, Giusj Monia, et al.
Publicado: (2023)

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation
por: Andersson, E I, et al.
Publicado: (2013)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML
por: Bargal, Salma A., et al.
Publicado: (2018)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

HOXA11 plays critical roles in disease progression and response to cytarabine in AML
por: Fu, Jen-Fen, et al.
Publicado: (2021)

Disrupting the LC3 Interaction Region (LIR) Binding of Selective Autophagy Receptors Sensitizes AML Cell Lines to Cytarabine
por: Putyrski, Mateusz, et al.
Publicado: (2020)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
por: Tabe, Yoko, et al.
Publicado: (2018)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
por: Kangaspeska, Sara, et al.
Publicado: (2016)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
por: Gupta, Abhishekh, et al.
Publicado: (2020)

Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial
por: Rubnitz, Jeffrey E., et al.
Publicado: (2009)

Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients
por: SHIBAYAMA, YOSHIHIKO, et al.
Publicado: (2015)

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML)
por: Omsland, Maria, et al.
Publicado: (2016)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine
por: Khaleel, Bara’ah, et al.
Publicado: (2023)

Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness
por: Karvonen, Hanna, et al.
Publicado: (2020)

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
por: Ali, Mehreen, et al.
Publicado: (2018)

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
por: Tomic, Barbara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rtd20p8v7fas60ubrkh42qhhdt